CORRESP 1 filename1.htm gnpx20230521_corresp.htm

picture2023.jpg

 

3300 Bee Cave Road, #650-227

Austin, TX 78746

 

June 7, 2023

 

VIA EDGAR

 

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jason Drory

 

Re:           

Genprex, Inc.

 

Registration Statement on Form S-3

  Filed on April 21, 2023

 

File No. 333-271386

  Acceleration Request
  Requested Date: June 9, 2023
  Requested Time: 4:30 p.m., Eastern Time

 

Ladies and Gentlemen:

 

In connection with the above-captioned Registration Statement (the "Registration Statement"), and pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), Genprex, Inc. (the "Company") hereby requests that the above-mentioned Registration Statement be declared effective by the Securities and Exchange Commission (the "Commission") at 4:30 p.m., Eastern Time, on June 9, 2023, or as soon thereafter as practicable.

 

Please call Alan Wovsaniker of Lowenstein Sandler LLP at 973-597-2564 to confirm the effectiveness of the Registration Statement or with any questions that you may have.

 

                    

 

GENPREX, INC.

 

 

 

By:

/s/ Ryan M. Confer

 

Name:

Ryan M. Confer

 

Title:

Chief Financial Officer